Sucheta M. Joshi, MD, MS, FAES, FAAP, and Nicholas Beimer, MD, discussed the reasons why EpiTRAQ may influence earlier discussions with patients prior to the epilepsy transition process.
The clinical professor of neurology at Stanford University School of Medicine talked about the collaboration of Rapport leveraging NeuroPace’s data analysis capabilities to study the target delivery of a therapy for focal epilepsy. [WATCH TIME: 5 minutes]
The neurologist at University of Utah discussed the potential of using teleneurology to diagnose neurological conditions.
The senior VP of clinical research at Eisai discussed findings from a phase 2 study assessing irsenontrine in patients with dementia with Lewy bodies and Parkinson disease dementia. [WATCH TIME: 4 minutes]
Mindy K. Bixby, DO and Laxman Bahroo, DO give key advice to community neurologists and emphasize the importance of effective communication between patients and providers.
Episode 7 of the AUPN Leadership Minute features Donald S. Higgins Jr., MD, of the VHA; and Justin C. McArthur, MBBS, MPH, of Johns Hopkins University. [WATCH TIME: 4 minutes]
The associate professor of neurochemistry at the University of Gothenburg in Sweden talked about a pilot study that explored the potential of finger prick tests to remotely collect blood and provide reliable biomarker results for Alzheimer disease diagnosis. [WATCH TIME: 5 minutes]
The professor of neurology and pediatrics at the University of Alabama at Birmingham Epilepsy Center provided perspective on the strides made with detection and treatment of infantile spasms. [WATCH TIME: 3 minutes]
The professor of pediatrics at Case Western University discussed the complexities and negative effects for children drastically change their sleep schedules as school begins. [WATCH TIME: 3 minutes]
There should be a holistic approach to how the systems in place affect equity: how medicine is practiced and research is conducted, the structure of academic institutions, and how media influence our perceptions of neurologic conditions.
The professor of materials science and engineering at Cornell University and chief executive officer at Artificial Axon Labs talked about the development of artificial axons through 3D printing. [WATCH TIME: 6 minutes]
Neurology experts discuss the unmet needs in narcolepsy treatment and share clinical pearls from their experiences.
The associate professor of pediatrics at the University of Colorado School of Medicine talked at the 2023 MDA Conference about how digestive health impacts patients with Duchene Muscular Dystrophy. [WATCH TIME: 4 minutes]
The professor of emergency medicine at Washington University in St. Louis and associate professor of neurosurgery at UTHealth Houston talked about results from the phase 3 MOST trial assessing argatroban and eptifibatide in acute ischemic stroke. [WATCH TIME: 3 minutes]
The internal medicine physician and chief medical officer and head of development at Pear Therapeutics offered his perspective on the current focus that is given to sleep in clinical care and the lack of education on interventions. [WATCH TIME: 2 minutes]
The chief medical officer at Alzheon provided perspective on the next steps for ALZ-801 following a successful phase 2 study of patients with APOE ε4/4 or APOE ε3/4 genotype. [WATCH TIME: 2 minutes]
As many as 1 in 3 infected with COVID-19 have longer-term neurological or mental health symptoms.
The chairman of the Clinical Advisory Committee of the New England Chapter of the National MS Society addressed the role DMTs play in patient response to the COVID-19 vaccine.
The clinical assistant professor of neurology at Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, New York, talked about her presentation on Evusheld at the 2023 ACTRIMS Forum. [WATCH TIME: 5 minutes]
The assistant director of computational biology at Stanford University discussed where the Alzheimer disease community stands on gene therapies that target APOE, and whether missense variants will play a role. [WATCH TIME: 4 minutes]
Experts share insights on the latest innovations in multiple sclerosis research, in highlights from a recent State of the Science SummitTM, presented by Neurology Live®.
From Standard-of-Care Injectables to Next-Generation S1P Receptor Modulators, Newer Treatments Offer Patients Options
The chief executive officer at Parkinson & Movement Disorder Alliance and the president at PD Avengers discussed the importance of awareness in movement disorders and the challenges that patients still face in getting access to treatments for improved quality of life. [WATCH TIME: 12 minutes
As the field of MS care turns its sights on addressing progressive disease, the need for more biomarkers of disease activity and therapeutic target engagement is perhaps greater than ever.
Episode 23 of the AUPN Leadership Minute features Donald S. Higgins, Jr., MD, of the VHA and Albany Medical College; and Robert Holloway, MD, MPH, of University of Rochester School of Medicine and Dentistry. [WATCH TIME: 6 minutes]
The neurologist at Lenox Hill Hospital detailed the findings of his observational study that looked at patterns of COVID-19 infections in patients with multiple sclerosis.
The professor of ophthalmology and neurology at Duke University School of Medicine talked about a recent published study on using artificial intelligence and retinal scans to detect mild cognitive impairment in neurodegenerative diseases including Alzheimer disease. [WATCH TIME: 7 minutes]
The associate professor of neurology at Harvard Medical School discussed findings from a study investigating nasal foralumab in patients with non-active secondary progressive multiple sclerosis. [WATCH TIME: 5 minutes]
A trio of experts from university hospitals discussed a study that aimed to uncover the prevalence and associations of limb swelling in patients with Dravet syndrome in hopes of improving care. [WATCH TIME: 5 minutes]
The chief medical officer of Biohaven Pharmaceuticals discussed the findings of an assessment of rimegepant (Nurtec ODT) exposure with concomitant administration of inhibitors of P-gp and BCRP transporters.